Market Access Views & Analysis

Views & Analysis

Market Access

Man listening to Podcast with Alice Valder Curran about Medicare drug pricing negotiations

Medicare drug pricing negotiations: What comes next?

Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the

Market Access

The benefits of ePI for patients and the planet

With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.

Market Access

Life sciences real estate is booming amid looming ‘patent cl...

The life sciences sector across Europe has remained remarkably resilient in recent years, with record levels of growth and investment.

Market Access

Changing Faces: Agency, consultancy, and investor hires for ...

Just a quick write-up this month for agency, consultancy, and investor hires.

Market Access

Balancing innovation and safety: The impact of Medtech regul...

The Medtech sector is currently at a crossroads, facing a potential choice between rapid technological advancement and strict regulatory oversight.

Market Access

Drug pricing overhaul sparks tension with industry

Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.

Medicare drug pricing negotiations: What comes next?

The benefits of ePI for patients and the planet

Life sciences real estate is booming amid looming ‘patent cl...

Changing Faces: Agency, consultancy, and investor hires for ...

Balancing innovation and safety: The impact of Medtech regul...

Drug pricing overhaul sparks tension with industry

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks